Business

Boehringer Ingelheim makes many of its best molecules openly available to the scientific community via opnMe.com to unlock their full potential

Boehringer Ingelheim

Boehringer Ingelheim has announced the launch of opnME.com, a new platform offering free and open access to selected pre-clinical molecules for non-clinical investigation to scientists worldwide. Through opnME.com, molecules for some of the most relevant targets in biomedical research are shared, thereby creating possibilities for further independent and collaborative discovery as well as the identification of novel treatment approaches for patients.

Roche to acquire Viewics, Inc. to provide data-driven lab business analytics and add further digital capabilities along the laboratory value chain

Roche

Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced an agreement with Viewics, Inc., a privately held software company focused on laboratory business analytics. Under the agreement, Roche is acquiring all shares of the company. The acquisition, which is subject to customary closing conditions, is expected to close on November 21, 2017.

Roche's OCREVUS (ocrelizumab) gains positive CHMP opinion for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis

Roche

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of OCREVUS for people with active relapsing forms of multiple sclerosis defined by clinical or imaging features and for people with early primary progressive multiple sclerosis in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.

Switching to Tresiba® is highly cost-effective and cost-saving in a real-world setting

Novo Nordisk

A new analysis of real-world data has shown that switching to Tresiba® (insulin degludec) is highly cost-effective and cost-saving for the treatment of type 1 and type 2 diabetes, respectively.(1) The analysis was presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR 2017) 20th Annual European Congress.

Merck and Samsung BioLogics to extend strategic alliance

Merck

Merck, a leading science and technology company, today announced the signing of a Memorandum of Understanding (MoU) with Samsung BioLogics for a strategic alliance on biopharmaceutical manufacturing and biologics process development. The alliance would accelerate process development and clinical material production at small biotech start-ups focusing on novel drug development for which Samsung BioLogics acts as a contract manufacturer.

BIOCAD enters the European market

BIOCAD

The largest Russian biotechnology company BIOCAD plans to enter the European market with oncological and autoimmune medicines. So far, there are seven molecules in the European portfolio of BIOCAD. These are innovative and biosimilar products, which could be used in treatment of melanoma, breast, stomach, kidney and lung cancer, rheumatoid arthritis, psoriasis and multiple sclerosis.

DSM brings innovative therapeutic concepts to CPhI 2017

Royal DSM

Royal DSM, a global science-based company active in health, nutrition and materials, is to showcase new therapeutic concepts featuring active pharmaceutical ingredients (APIs), particularly vitamins and lipids for pharmaceutical applications, at CPhI. Covering diverse fields such as hypertension, diabetes, irritable bowel syndrome, breast cancer, prostate cancer and multiple sclerosis, the concepts demonstrate how DSM can use its high quality products to innovate and support customers in getting to market faster.

Business

More Pharma News ...